ViroPharma (VPHM)
ViroPharma Cash and ST Investments: 473.36M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VPHM Cash and ST Investments Rankings
| Overall | 80th percentile | 857 of 4370 |
| Sector | 88th percentile | 60 of 506 in Healthcare |
| Industry | 93rd percentile | 10 of 160 in Biotechnology |
VPHM Cash and ST Investments Range, Past 5 Years
| Minimum | 245.21M | Mar 2009 |
| Maximum | 668.36M | Sep 2008 |
| Average | 455.03M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these VPHM related companies
VPHM News
Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates ViroPharma, Inc. For Securities Fraud
May 31, 7:45AM Business Wire
May 31, 7:45AM Business Wire
Izard Nobel LLP Announces Class Action Lawsuit Against ViroPharma Incorporated
May 24, 4:59PM Marketwire
May 24, 4:59PM Marketwire
Pomerantz Law Firm Has Filed a Class Action Against ViroPharma Incorporated -- VPHM
May 22, 6:25PM GlobeNewswire
May 22, 6:25PM GlobeNewswire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ViroPharma Incorporated
May 18, 12:58PM Business Wire
May 18, 12:58PM Business Wire
$VPHM Market does seem to be pricing in the decimation of Vancocin. http://stks.co/3c6k
about 31 days ago by birllc
about 31 days ago by birllc
Video of our entry ideas today in $AKAM $VPHM $AIG $NI $MAS $HUN $TSL - http://stks.co/3byB
about 31 days ago by greatstockpix
about 31 days ago by greatstockpix
$VECO up 12% on earnings. $VPHM down 10%. $DEXO continues its descent into oblivion, down 10% to $0.87.
about 31 days ago by MagicDiligence
about 31 days ago by MagicDiligence
Listen to $VPHM Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3bA1
about 31 days ago by earningscast
about 31 days ago by earningscast
Viropharma, Inc. (VPHM) Misses Q1 EPS by 5c; Guides FY12 Revs Below Views
May 01, 6:30AM Street Insider
May 01, 6:30AM Street Insider
$VPHM BioLogic Equity Research – ViroPharma Report Library - http://stks.co/3Vwl
about 37 days ago by birllc
about 37 days ago by birllc
Following...fresh face RT @birllc $VPHM - ViroPharma without Vancocin is Breakeven at Best - http://stks.co/3VsM
about 37 days ago by howardlindzon
about 37 days ago by howardlindzon
$VPHM - ViroPharma without Vancocin is Breakeven at Best - http://stks.co/3Vm8
about 37 days ago by birllc
about 37 days ago by birllc
yestereday wuz huge newz 4 $AKRX. this will take market share frum $VPHM soon. already strong earningz without Vanoccin. $20 runup
about 37 days ago by johnkelly
about 37 days ago by johnkelly
ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012
Apr 23, 4:00PM PR Newswire
Apr 23, 4:00PM PR Newswire
Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated
Apr 20, 4:01PM Business Wire
Apr 20, 4:01PM Business Wire
$VPHM is -5.1% down since open on unusual high volume and -5.9% down since close.
about 46 days ago by TradeBot
about 46 days ago by TradeBot
@johnkelly Haven't really followed the generics. It's not just $AKRX but also $WPI in competition w $VPHM.
about 51 days ago by abubnic
about 51 days ago by abubnic
$VPHM Concern about generic competition for Vancocin, which brings in about 50% of revenue. http://stks.co/3J6j
about 51 days ago by abubnic
about 51 days ago by abubnic
RT @daytrend $VPHM poster child for why many traders don't touch biotechs.
about 51 days ago by jamiemc101
about 51 days ago by jamiemc101
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VPHM | 20.14 | -0.12 | -0.59% | 1.425B |
| VPG | 13.91 | +0.04 | +0.29% | 171.37M |
| VPFG | 15.25 | -0.01 | -0.07% | 513.92M |
| VASC | 11.38 | -0.08 | -0.70% | 189.14M |
| VAR | 58.66 | -1.23 | -2.05% | 6.628B |
| VALV | 0.85 | -0.06 | -6.08% | 14.14M |
| VALU | 12.25 | +0.08 | +0.66% | 121.28M |
| VALE | 18.31 | -0.12 | -0.65% | 58.04B |
| VAL | 48.21 | -0.33 | -0.68% | 4.489B |
| V | 115.20 | -2.29 | -1.95% | 93.67B |